Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Island Pharmaceuticals Ltd ( (AU:ILA) ) has shared an update.
Island Pharmaceuticals Ltd has secured approximately $1 million in new funding through the exercise of options by directors and substantial shareholders. This capital injection enhances the company’s financial position, supporting the clinical development and commercial readiness of Galidesivir, a broad-spectrum antiviral. The funding will aid regulatory initiatives under the FDA Animal Rule and US Government engagement, positioning Galidesivir for potential inclusion in national stockpiles as a critical antiviral countermeasure. The investment reflects confidence in Island’s strategy and its ability to advance Galidesivir towards potential approval and strategic value creation.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian company focused on developing antiviral drugs to address urgent viral diseases, public health, or biosecurity threats. The company is advancing a dual development strategy with its assets, ISLA-101 and Galidesivir. ISLA-101 is being repurposed for dengue fever and other mosquito-borne diseases, while Galidesivir is a clinical-stage antiviral targeting over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever.
Average Trading Volume: 798,013
Technical Sentiment Signal: Buy
Current Market Cap: A$132.4M
Find detailed analytics on ILA stock on TipRanks’ Stock Analysis page.